Vifor Pharma Nederland B.V.

Vifor Pharma AG develops, manufactures, and distributes pharmaceutical products in Switzerland, Europe, the United States, and internationally. It offers iron products, including Ferinject, Venofer, Maltofer, and Velphoro; Veltassa, a sodium-free potassium binder for the treatment of hyperkalaemia in adult patients; and Mircera, an erythropoiesis-stimulating agent for the treatment of symptomatic anemia associated with chronic kidney diseases. The company also provides infectious diseases/over-the-counter products, such as Broncho-Vaxom, an extract of various bacterial species for the treatment and prevention of recurrent respiratory infections; Uro-Vaxom, an extract of the bacterium Escherichia coli for the treatment and prevention of recurrent urinary tract infections; Dicynone for the prevention and treatment of capillary haemorrhages; Doxium for the oral treatment of diabetic retinopathy; and Aero-OM, an anti-flatulent for the oral treatment. Its development/pre-clinical products include VIT-2763, an oral ferroportin inhibitor, which is Phase I clinical trial for the treatment patients suffering from iron overload; Rayaldee for the treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) and vitamin D deficiency; Biosimilar epoetin alfa the treatment of anemia associated with CKD, renal failure, and chemotherapy-induced anemia; Avacopan/CCX168, an orally administered inhibitor; CCX140, an orally administered inhibitor of the chemokine receptor; and Vadadustat, an oral investigational hypoxia-inducible factor stabiliser that is in Phase-III development for the treatment of anemia related to CKD. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1927 and is headquartered in St. Gallen, Switzerland.